logo
Scientists Created an Antimatter Qubit That Could Upend Physics

Scientists Created an Antimatter Qubit That Could Upend Physics

Yahooa day ago
"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links."
Here's what you'll learn when you read this story:
The explanation behind the universe's matter-antimatter asymmetry—an apparent violation of a fundamental law of nature known as charge-parity-time (CPT) symmetry—is one of particle physics' greatest mysteries.
A new study details how scientists at CERN created antimatter qubits, which could improve physicists investigations into magnetic moment differences between matter and antimatter.
This breakthrough—along with CERN's ongoing effort to protect the transport of particles to other laboratories—could drastically improve baryonic antimatter research.
The universe is filled with something instead of nothing—and that's a problem. Well, a quick clarification: This unexplainable quirk of science is great news for you, me, and every other living being throughout the cosmos, since it means that we (being made of matter) get to exist. But from a particle physicist's perspective, it represents a massive gap of knowledge in the Standard Model, which is our current best guess at explaining the strange world of the subatomic.
The Swiss-based particle physics laboratory CERN, home of the Large Hadron Collider, is at the forefront of exploring this particular unknown, which is an apparent violation of a fundamental law of nature known as charge-parity-time (CPT) symmetry. This nearly 75-year-old theory posits that matter and antimatter behave identically, meaning that they should have annihilated each other mere moments after the Big Bang. But for some reason, matter prevailed.
Now, a recent study—led by scientists at CERN and published in the journal Nature—details a new tool in their exploratory toolbox for trying to understand why the universe contains something instead of nothing. At its most basic, researchers created the world's first antimatter 'qubit'—the quantum-powered building blocks of quantum computers—in an effort to study matter-antimatter asymmetry with higher fidelity. This was achieved by the Baryon Antibaryon Symmetry Experiment (BASE) collaboration using the antimatter factory at CERN.
Like most things that deal with quantum properties, the main challenge was keeping the antiproton from experiencing decoherence, in which a qubit loses its quantum properties via disruptions from the surrounding environment. The researchers successfully kept the antiproton trapped and oscillating smoothly between quantum states for almost a minute and then measured transitions between magnetic moments using a process known as 'coherent quantum transition spectroscopy.' Although an incredibly complicated process, CERN describes this method like pushing a child on a swingset:
With the right push, the swing arcs back and forth in a perfect rhythm. Now imagine that the swing is a single trapped antiproton oscillating between its spin 'up' and 'down' states in a smooth, controlled rhythm. The BASE collaboration has achieved this using a sophisticated system of electromagnetic traps to give an antiproton the right 'push' at the right time. And since this swing has quantum properties, the antimatter spin-qubit can even point in different directions at the same time when unobserved.
This qubit isn't destined to run in some hyper-advanced quantum computer. Instead, its role lies in exploring the very edge of the standard model of particle physics. Previously, BASE collaboration has shown that magnetic moments of protons and antiprotons are identical up to just a few parts-per-billion—any detectable deviation would violate CPT symmetry and possibly explain why protons outnumbered antiprotons following the Big Bang. However, these results used incoherent techniques impacted by magnetic field fluctuations and perturbations caused by the measurements themselves. This new technique suppresses those interferences and makes coherent observations that are many times more accurate than previous magnetic moment experiments.
'This represents the first antimatter qubit and opens up the prospect of applying the entire set of coherent spectroscopy methods to single matter and antimatter systems in precision experiments,' BASE spokesperson Stefan Ulmer, a co-author of the study, said in a press statement. 'Most importantly, it will help BASE to perform antiproton moment measurements in future experiments with 10- to 100-fold improved precision.'
And this new level of precision is only the beginning. A simultaneous effort known as BASE-STEP (Symmetry Tests in Experiments with Portable Antiprotons) utilizes a portable trap system so antiprotons can be transported to other facilities with more stable environments. In October of last year, BASE-STEP successfully transported 70 protons via truck on a round trip at CERN's main site. This will allow labs throughout Europe—and maybe, one day, the world—to work on one of physics' most puzzling mysteries.
You Might Also Like
The Do's and Don'ts of Using Painter's Tape
The Best Portable BBQ Grills for Cooking Anywhere
Can a Smart Watch Prolong Your Life?
Solve the daily Crossword
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

The Blood Type Diet Is Popular Again. Here's What the Science Says.
The Blood Type Diet Is Popular Again. Here's What the Science Says.

Yahoo

time5 hours ago

  • Yahoo

The Blood Type Diet Is Popular Again. Here's What the Science Says.

"Hearst Magazines and Yahoo may earn commission or revenue on some items through these links." PEOPLE OFTEN ADOPT different diets for different reasons. They may start eating Mediterranean-style to improve their heart health, or go vegan for ethical reasons. But what about eating according to your blood type? This idea was first introduced in a 1996 book, Eat Right 4 Your Type, by naturopathic physician Peter D'Adamo, which suggested that people could improve their health, live longer, and maintain their ideal weight by eating specific food groups based on their blood type, according to Harvard Medical School. More recently, TikTokers have been talking about the blood type diet and its purported benefits and downsides. But is there any scientific evidence that the diet works? Here's what experts say. What Is the Blood Type Diet? THE BLOOD TYPE diet outlines who should eat what based on their blood type, explains Liz Weinandy, M.P.H., R.D.N., a registered dietitian nutritionist and instructor of practice in medical dietetics at The Ohio State University Wexner Medical Center. This is what the diet suggests, for example: People with type O blood should consume high-protein foods, including meat, fish, fruits, and vegetables, but limit legumes and whole grains. People with type A should eat a vegetarian diet, with lots of fruits, vegetables, and whole grains, and avoid meat. People with type B or AB blood should eat a balanced diet covering all food groups. The theory is that there's a link between blood type and how well you digest different foods, and that eating based on blood type could improve digestion, help maintain a healthy weight, boost energy, and lower your risk of disease. For example, the book links type O is to the earliest humans, who were hunter-gatherers and ate mostly animal proteins. Type A possibly evolved after humans began farming and ate more fruits and vegetables, while B types may have arisen from nomadic tribes who ate dairy. AB eating recommendations are between the suggestions for types A and B. Does It Work? THERE'S NOT ENOUGH scientific evidence to suggest that it does, as no high-quality studies have been done to verify claims about the blood type diet, explains Randy Gould, D.O., a cardiologist at Manhattan Cardiology and a contributor to LabFinder. A 2013 systematic review found no studies showing benefits of a blood type diet. However, a 2014 study suggested that people who followed a blood type diet had lower BMI, waist circumference, blood pressure, cholesterol, and blood sugar—but the improvements weren't actually linked to subjects' blood types. Blood type also wasn't linked to improvements in body weight, body fat, blood lipids, or glycemic control for people who followed a low-fat vegan diet, according to research published in 2021. Any potential benefits of the diet are likely to do with what it encourages people to eat and not eat, rather than their actual blood type. 'All three types of diets for different blood types encourage many fruits and vegetables and also avoidance of ultra-processed foods,' Weinandy says. 'This is healthy for anyone.' It's also important to note that blood type may play a role in other aspects of health, Dr. Gould says. Some studies have shown that people with type O blood have a lower risk for heart disease compared to people with types A, B, and AB. And, people with type A or AB may be at a higher risk for gastric cancer, and types A, B, and AB at a higher risk for pancreatic cancer, according to Northwestern Medicine. Who Should (and Shouldn't) Try the Diet? ONE BARRIER TO trying the diet is that most people actually don't know their blood type, according to the American Red Cross. To find out, you can ask your doctor to test it, or if you donate blood, they can likely tell you. Trying the blood type diet could be beneficial for people who don't normally eat many fruits, vegetables, or whole grains, Dr. Gould says. However, it's 'very prescriptive and lacking in evidence,' Weinandy says. 'Cutting out entire food groups like dairy or even wheat when it likely isn't necessary can cause inadequate nutrient intake.' She doesn't recommend the blood type diet to anyone: 'Like most unproven diets and claims, there may be some truth or good points to it—in this case, eating a lot of whole plant foods—but it's surrounded by negatives like cutting out food groups.' Instead, Weinandy suggests following the Mediterranean diet, which she says is less restrictive, includes a wide range of food groups, and has lots of research to show it improves health. You Might Also Like The Best Hair Growth Shampoos for Men to Buy Now 25 Vegetables That Are Surprising Sources of Protein

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Yahoo

time18 hours ago

  • Yahoo

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma
Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Yahoo

time18 hours ago

  • Yahoo

Press Release: Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma

Sanofi's SAR446523, a GPRC5D monoclonal antibody, earns orphan drug designation in the US for multiple myeloma Designation granted for IgG1-based GPRC5D monoclonal antibody for the potential treatment of patients with relapsed or refractory multiple myeloma Paris, July 30, 2025. The US Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an IgG1-based Antibody-Dependent Cellular Cytotoxicity-enhanced (ADCC) monoclonal antibody (mAb) targeting G-protein coupled receptor family C group 5 member D (GPRC5D) for the potential treatment of patients with relapsed or refractory multiple myeloma (R/R MM). GPRC5D is highly expressed on plasma cells in MM patients, with low expression in healthy tissues. The FDA grants orphan drug designation to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people in the US. 'The orphan drug designation is a significant milestone in our ongoing efforts to develop innovative treatments in multiple myeloma,' said , Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi. 'This underscores our commitment to multiple myeloma, a disease for which we have acquired strong expertise with the development of another widely used and approved immunotherapy treatment.' The safety and efficacy of SAR446523 has not been evaluated by any regulatory authority and is still under investigation. About SAR446523SAR446523 is an investigational IgG1-based mAb designed to target GPRC5D, which is highly expressed on plasma cells, with an engineered fragment crystallizable domain to enhance antibody dependent cell-mediated cytotoxicity. This innovative approach aims to improve the efficacy of treatment for MM, a rare and challenging cancer of plasma cells. Subcutaneous SAR446523 is currently being evaluated in an ongoing phase 1, first-in-human study in patients with R/R MM (clinical study identifier: NCT06630806). SAR4465523 originates from Sanofi Research in Vitry-sur-Seine, France. About multiple myelomaMultiple myeloma is considered a rare disease, yet MM is the second most common hematologic malignancy with more than 180,000 people diagnosed with MM each year, globally. Despite available treatments, MM remains an incurable malignancy with an estimated 62% five-year survival rate for newly diagnosed patients. There is a need for new frontline therapeutic options for all patients, especially for those who are transplant ineligible, due to high attrition rates in subsequent lines of therapy. Since MM does not have a cure, most patients will relapse and stop responding to therapies they have received. At Sanofi, we are building on a long-standing commitment to oncology as we continue to chase the miracles of science to improve the lives of those living with cancer. We are committed to transforming cancer care by developing innovative, first and best-in-class immunological and targeted therapies for rare and difficult-to-treat cancers with high unmet need. For more information on MM clinical studies, please visit About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people's lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY Media RelationsSandrine Guendoul | +33 6 25 09 14 25 | Berland | +1 215 432 0234 | Léo Le Bourhis | +33 6 75 06 43 81 | Victor Rouault | +33 6 70 93 71 40 | Timothy Gilbert | +1 516 521 2929 | Ubaldi | +33 6 30 19 66 46 | Investor RelationsThomas Kudsk Larsen |+44 7545 513 693 | Alizé Kaisserian | +33 6 47 04 12 11 | Lauscher | +1 908 612 7239 | Keita Browne | +1 781 249 1766 | Pham | +33 7 85 93 30 17 | Elgoutni | +1 617 710 3587 | Thibaud Châtelet | +33 6 80 80 89 90 | Yun Li | +33 6 84 00 90 72 | Sanofi forward-looking statementsThis press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words 'expects', 'anticipates', 'believes', 'intends', 'estimates', 'plans' and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under 'Risk Factors' and 'Cautionary Statement Regarding Forward-Looking Statements' in Sanofi's annual report on Form 20-F for the year ended December 31, 2024. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. All trademarks mentioned in this press release are the property of the Sanofi Press Release

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store